Announcements Trials

Browse Landscape

Phase

Status

Recruiting 7 Completed 6 Unknown 2 Terminated 2 Active not recruiting 2 Withdrawn 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 4 Gastrointestinal 2 Plasma cell 1 Head & Neck 1 Dermatologic 1 CNS 1 Breast 1

Conditions

Interventions

Nivolumab 18 Ipilimumab 16 pembrolizumab 15 Cyclophosphamide 13 trametinib 9 Radiotherapy 8 dabrafenib 6 Interleukin-2 6 sargramostim 5 fludarabine phosphate 5 aldesleukin 5 Vemurafenib 5 Peripheral Blood Stem Cell Transplantation 5 Fluorouracil 5 130-nm albumin-bound paclitaxel 5 fludarabine 4 Radiosurgery 4 Melphalan 4 Celecoxib 4 encorafenib 3 durvalumab 3 binimetinib 3 avelumab 3 Vorinostat 3 Specimen Handling 3 Magnetic Resonance Spectroscopy 3 Leucovorin 3 Granulocyte-Macrophage Colony-Stimulating Factor 3 Cytarabine 3 Capecitabine 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Immunotherapy × Dermatologic × Clear all

NCT04242329 2024-01-26

SUMMIST

Vastra Gotaland Region

Phase 2 Withdrawn

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡